In this episode, we talk with Richard Xie, Senior Health Economist at RA Capital, and Gunnar Esiason, Senior Director of Patient Engagement at Raven (RA Capital Ventures), about value frameworks in pharma. We unpack how Generalized Cost-Effectiveness Analysis (GCEA) builds on traditional Cost-Effectiveness Analysis (CEA) and differs from ICER’s model. The conversation explores what these approaches mean for pricing, access, and patient voice—especially in rare and high-innovation settings.

Through the Cidara CD388 flu drug case, we discuss how assumptions shape value and trade-offs from manufacturer and patient perspectives. The episode highlights how evidence, incentives, and outcomes align—or conflict—in today’s system, and what reforms could better connect value frameworks to affordability and equitable access.

• Richard Xie, Senior Health Economist, RA Capital Management
• Gunnar Esiason, MBA, MPH, Senior Director, Head of Patient Engagement and Patient-Centered Innovation, Raven (RA Capital Ventures)
• Patient-Centered Value Assessment Models
• Episode 26: Sarah Emond, ICER
• Peter Kolchinski, The Great American Drug Deal
• NICE (UK)
• CDA (Canada)
• Australia CHAP
• Trikafta
• ICER Report on Cystic Fibrosis
• No Patient Left Behind
• GCEA Calculator
• Boomer Esiason Foundation
• Aurora Biosciences
• Most-Favored-Nation Drug Pricing Order

Questions or comments? Email [email protected].

Follow us on X, LinkedIn, YouTube, and Threads.